AbramsP.H., ShahP.J.R., StoneR., ChoaR.G.: Bladder out flow obstruction treated with phenoxybenzamine. Brit. J. Urol., 54; 527 (1982).
2.
AwadS.A., DownieJ.W.: The effect of adrenergic drugs and hypogastric nerve stimulation on the canine urethra: a radiologic and urethral pressure study. Invest. Urol., 13; 298 (1976).
3.
BlaivasI.G.: Pathophysiology and differential diagnosis of benign prostatic hypertrophy. Urology, 32; 5–10 (1988).
4.
BorehamP.F., BraitahwaiteP., MilewskyP., PearsonH.: Alpha-adrenergic blockers in prostatism. Brit. J. Surg., 64; 756 (1977).
5.
CaineM.: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J. Urol., 136; 1 (1986).
6.
CaineM., PfauA., PerlbergS.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Brit. J. Urol., 48; 255 (1976).
7.
CaineM., PerlbergS., MeretykS.: A placebo controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Brit. J. Urol., 50; 551 (1978).
8.
CaineM., RazS., ZeiglerM.: Adrenergic and cholinergic receptors in the humane prostate, prostatic capsule and bladder neck. Brit. J. Urol., 47; 193 (1975).
CaineM.: Alpha adrenergic mechanism in dynamics of benign prostatic hypertrophy. Urology, 32; 16 (1988).
11.
DunzendorferU.: Clinical experience with symptomatic management of BPH with terazosin. Urology, 32; Suppl. 6; 27 (1988).
12.
EkA.: Adrenergic and cholinergic nerves of the human urethra and urinary bladder: a histochemical study. Acta Physiol. Scand., 99; 245 (1977).
13.
GerstenbergT.C.: Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic obtruction: a urodinamic investigation. Invest. Urol., 18; 29 (1980).
14.
GibertiC.: The effect of thymoxamine in benign prostatic hypertrophy: a double blind cross-over study. IRCS med. Sci., 12; 591 (1984).
15.
HedlundH., AnderssonK.E., EkA.: Effects of prazosin in patients with benign prostatic obstruction. J. Urol., 130; 275 (1983).
16.
HiebleJ.P., BoyceA.J., CaineM.: Comparison of the alpha adrenoceptor characteristic in human and canine prostate. Fed. Proc, 45; 2609 (1986).
17.
IacovouJ.W., DunnM.: Indoramin - an effective new drug in the management of bladder outflow obstruction. Brit. J. Urol., 60; 526–528 (1987).
18.
JardinA.: Efficacité d'un alpha-bloquant: l'Alfuzosine, sur le troubles mictionnels des hommes porteurs d'adénome prostatique. Résultats intermédiaires d'une étude mul-ticentrique européenne. Ann. d'Urol., 22; 333–340 (1988).
19.
KawabeK., NiijimatT.: Use of alpha-blocker, YM-12617, in micturiction difficulty. Urol. Intern., 42; 280 (1987).
20.
Kir-byR.S., CoppingerS.W.C., CorcoranM.V., ChappieC.R., FlanniganM., MilroyE.J.G.: Prazosin in the treatment of prostatic obtruction. A placebo controlled study. Brit. J. Urol., 60; 136 (1987).
21.
LeporH., GupD.I., BaumannM., ShapiroE.: Laboratory assessment of terazosin and alphai blockade in prostatic hyperplasia. Urology, 32; Suppl. 6; 21 (1988).
22.
MartoranaG.: The effect of Prazosin in benign prostatic hypertropy, a placebo controlled double blind study. IRCS. med. Sci., 12; 11 (1984).
23.
NegardhA.: The interaction between adrenergic and cholinergic receptor functions in the outlet region of the urinary bladder. Scand. J. Urol. Nephrol., 8; 108 (1974).
24.
NegardhA.: Autonomic receptor functions in the lower urinary tract: a survey of recent experimental results. J. Urol., 113; 180 (1975).
25.
NorlenL.: Influences of the sympathetic nervous system on the lower urinary tract and clinical implication. Neurourol. Urodinam., 1; 125 (1982).
26.
ShapiroE., LeporH.: Alpha2 adrenergic receptors in hyperplastic human prostate: identification and characterization using (3H)-rauwolscine. J. Urol., 135; 1038 (1986).
27.
ShapiroA., MazouzB., CaineM.: The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol. Res., 9; 17 (1981).